Project description:Etrolizumab, a humanized monoclonal antibody that selectively binds the b7 subunit of the heterodimeric integrins a4b7 and aEb7, is currently in development for patients with moderate-to-severely active UC. Integrin aE forms a heterodimer with b7; and aEb7 interacts with E-cadherin to mediate retention of aEb7+ cells in the intestinal epithelium. Baseline integrin aE levels have been identified as a potential predictive biomarker for etrolizumab response. Materials and methods: Mucosal lymphocytes were isolated using a collagenase digestion from resected tissue from a patient without inflammatory bowel disease. Individual CD45+TCRab+TCRgd- cells were sorted into 96 well plates. Cell numbers were normalized across CD4+aE+, CD4+aE-, CD8+aE+ and CD8+aE- groups.
Project description:Breast tumors are characterized by inherent heterogeneity but the evolving cellular organization of breast tumors through progression remains poorly understood. Individual clones were tracked by combining mouse models of breast cancer with Confetti reporter strains. Expression profiling of individual clones sorted from tumors arising in K5- and Elf5-driven Pten/p53-deficient mice revealed distinct molecular signatures.
Project description:Single cell lung suspensions of explanted healthy and IPF donor lung tissue were generated. scRNA-seq was performed on EPCAM negative live cells sorted by FACS. Puried mesenchymal cells were clustered to evaluate the mesenchymal cell sub-clusters
Project description:This SuperSeries is composed of the SubSeries listed below. We analyze the transcriptomes of healthy donor and CD46 deficieint patients with and without in vitro activation by microarray and RNA-seq